2021 looks set to be a big year for cannabis reform in the US now that the new White House administration has signalled that cannabis reform is one of its top priorities, and the US public supports cannabis reform in unprecedented numbers.
Keep up to date with the latest changes in federal regulation impacting the US market for CBD market with news, data and research at the CBD-Intel hub.
Licensing issues look set to become the next big US lobbying battleground for cannabis as money moves on from the traditional legalisation-versus-prohibition field
CBD growth in the UK could be boosted by a report from a new taskforce on post-Brexit regulatory change. But how likely is it that the recommendations will be implemented?
As CBD grows in popularity, its regulatory status remains poorly defined. In this report CBD-Intel reviews the regulatory framework of dietary supplements and where CBD fits, or would fit, within that framework
Delta-8 THC has emerged as the hottest new cannabinoid in the US market. This report examines federal law on delta-8, notes trends that are happening at state level, and discusses what the future may hold
A CBD company has been fined more than $30,000 by the US Federal Trade Commission (FTC) in the first such punishment since a crackdown on false or misleading health claims was announced in December
Tim Phillips, CBD-Intel’s managing director, recently presented at CBD Live during VOXPO – Virtual Online Vape & CBD Expo on 28th April 2021. In addition to an overview of the impact of Covid-19 on the retail environment, he provided a comparative analysis of the current Novel Food legislation in the UK and the US, as […]
Significant cannabis reform is inevitably coming to congress, no matter whether the Biden administration considers it a priority, and giants in experienced lobbying industries are preparing their agents
A new deputy commissioner at the US Food and Drug Administration (FDA) will likely be the single person with the most influence on the path to market for CBD in the US
Access to banking services has been a problem for the legal cannabis sector in the US from the beginning – and the experience of one cooperative in Michigan shows that the relationship can be problematic for financial institutions too
The US Customs and Border Protection (CBP) agency is wrongly seizing legal hemp and hemp-related shipments – such as farm equipment that it claims constitutes drug paraphernalia – according to two recently-filed lawsuits
CBD companies see more synergies than threats from the provision of legal cannabis products in states such as Colorado, which has one of the oldest recreational cannabis markets in the US
The US Food and Drug Administration (FDA) has assessed a combined health claim for the first time and denounced the practice of promoting CBD on a product making qualified health claims based on other ingredients
The US Food and Drug Administration (FDA) has told two CBD companies they fell short of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and ordered them to undertake proper testing
Podcasts editor Jon Bruford is joined by Anthony Traurig, CBD-Intel legal analyst and US specialist, to discuss the legal and regulatory concerns that hang over cannabis in the US and Canada and the economic impact of Covid-19
CBD-Intel podcasts editor Jon Bruford is joined by the founder and principal of Kight Law Office, Rod Kight, a specialist in cannabis business law in the US
The heir to the Wrigley’s chewing gum fortune, Beau Wrigley, has entered into a deal he claims will accelerate the growth of his multi-state cannabis company, Parallel, and change the landscape of the US cannabis market
Marlboro cigarette manufacturer Altria has stated its support for the federal legalisation of cannabis – with a view to Cronos, the Canadian cannabis company in which it has a major stake, thriving in a legal US market
A US association of cannabis regulators has written to Congress urging the modernisation of cannabis policy at federal level
The US Federal Trade Commission (FTC) could take a more discerning approach to enforcement against CBD companies under the new administration in Washington
The Democratic Party, which now controls Congress and the presidency, has signalled for some time that cannabis reform is one of its top priorities, and the US public supports that reform in unprecedented numbers
US president Joe Biden’s appointees to a number of influential positions in the new administration give reason for optimism within the hemp and cannabis sector
The US Small Business Administration (SBA) has highlighted its role in securing changes to the Department of Agriculture (USDA)’s final rule for hemp production
CBD-Intel presents some predictions of what regulatory moves could take place around cannabis, hemp and CBD in the US in 2021
President elect Joe Biden still looks to be somewhat reluctant to too closely embrace cannabis reform as an issue. But effective control of the senate through victories by Raphael Warnock and Jon Ossoff in special run-off elections in the state of Georgia give Democrats 48 seats with two independents that generally vote democratic (and would […]
Reform of cannabis laws at federal level in the US looks to be a step closer following the likely victory of the Democratic party in run-off elections for both Senate seats in the state of Georgia
For many 2020 will always carry an asterisk. The CBD industry was – overall – more fortunate than many other sectors
Multiple jurisdictions are planning significant legislation on both CBD and hemp-related matters, but it seems regulation in 2021 could be defined as much by what doesn’t happen as by the progress made
The US Food and Drug Administration (FDA) is still working on a plan to standardise a baseline level of regulation for CBD in dietary supplements, food and drinks – but many in the industry and at state level are weary of waiting
Claims that CBD could help shrink tumours were among those censured by the US Food and Drug Administration (FDA) in its latest round of warning letters to the industry
The first ever fines – ranging up to $85,000 – have been issued to CBD companies by the US Federal Trade Commission (FTC) for deceptive marketing practices
Another company has been warned by the US Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) to stop claiming CBD can cure or mitigate the symptoms of COVID-19
Berta Camps Bisbal, CBD-Intel’s senior legal analyst, presented a comparative analysis of state laws in the US at CBD Live during VOXPO – Virtual Online Vape & CBD Expo on 18th November. She presented an overview of the federal farm bill as well as CBD at the federal level versus state level. You can now […]
With Joe Biden poised to become the 46th US president, lobbyists in Washington are scrambling to position themselves to influence cannabis policy
Expect US Food and Drug Administration (FDA) regulations on CBD by the second half of 2021, according to leading brand Charlotte’s Web
The US Food and Drug Administration (FDA) may be open to allowing CBD as an ingredient in dietary supplements as well as in food and drink products. However, the regulatory pathway is not clear
Investing activity in the cannabis space is on the rise, as investors take advantage of lower prices and companies seek opportunities to merge – bolstered by anticipated changes at US federal level
Well reported studies of labelling issues give unfair bad press to CBD – but it is an issue the industry urgently needs to address, according to speakers at the Food and Drug Law Institute’s annual conference
It remains unclear when, or whether, US FDA guidance on CBD enforcement policy will be published, according to speakers at the recent Food and Drug Law Institute annual conference
The National Advertising Division (NAD) of the US Better Business Bureau has referred advertising claims made by a CBD company to the Federal Trade Commission (FTC)
With US elections on 3rd November fast approaching, lobbyists for CBD, cannabis and hemp are eager to get their message across to candidates on both sides of the political divide
The apparently unrelated fields of red yeast rice and stem cell research could provide clues as to how the US Food and Drug Administration (FDA) might deal with market regulation of CBD
Should CBD or cannabis companies invest in the US or Canada? There are pros and cons to each, and the same answer may not apply to everyone – or remain the same forever
The US Congress has extended by 11 months the deadline for states to get into compliance with the 2018 Farm Bill
The US House of Representatives is expected to hold a historic vote this month on a comprehensive cannabis reform bill that supporters embrace for not only decriminalising marijuana but correcting injustices
More than a dozen CBD businesses have given their backing to an investigation of the impact of CBD on liver toxicity levels in order to provide regulatory authorities in the US with reliable new data
First it’s important to note that the DEA proposals are only in a draft form and are open to comment until 20th October. They have already received a large number of comments, the majority of which appear to be criticising aspects of the proposed regulatory regime that have raised hackles among the industry.
The pharmaceutical side of the cannabinoid industry continues to grow, with several major announcements expanding treatments and blurring boundaries
Proposed regulations from the US Drug Enforcement Administration (DEA) have riled the hemp and CBD sectors, with opinions divided on what the rule would mean if enacted in its current form
Charlotte’s Web has been denied a US trademark on appeal – a ruling that has serious implications for any company in the CBD sector selling food, drink or dietary supplement products in the US
Canopy, the Canadian cannabinoid company, has continued to commit heavily to BioSteel, a sports nutrition company in which Canopy now owns the majority share.
In December 2018 the Farm Bill removed hemp – defined as cannabis – and its derivatives, from the definition of marijuana in the Controlled Substances Act.
This paved the way for the legal cultivation, sale and distribution of the hemp plant but also led to led to the misperception that all products made from or containing hemp, including those made with CBD, were now legal to sell in interstate commerce.
Two years on, there is still a lack of clarity around what is and isn’t legal and the CBD industry is held back by lack of federal regulation and a patchwork of consumer and products safety standards and guidance.
Industry stakeholders have called for more joined up regulation, including increased protection of state legalisation frameworks, access to banking for cannabis firms, harmonised standards for consumer and product safety and lab testing, and relaxation of federal constraints on research.
With frustrations mounting over the Food and Drug Administration’s (FDA’s) slow pace, Congress could take matters into its own hands by passing legislation to move the industry forward.
Though Biden himself seemingly remains sceptical about recreational cannabis – having previously stated it should be placed in Schedule II under the Controlled Substances Act category – many of his major appointments appear to be solid supporters of hemp and cannabis, which gives the industry reason for optimism.
Stay on top of the ever-changing regulatory landscape with our CBD-Intel hub, which provides access to our news briefings, data and reports on developments related to US federal regulation.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
